Indian Drug Makers, Activists Say MNCs Hide Facts In Patents
This article was originally published in PharmAsia News
Executive Summary
Major Indian drug makers are joining with public-health activists to accuse multinational drug companies of being less than forthcoming in their patent applications. The Indian groups say the MNCs are attempting to hide the identity of the molecules they use in their formulas. A patent expert said some companies attempt to call their creations "a novel compound" or "new pharmaceutical substance" to avoid identification of the chemicals or molecules involved. He said there are rules against accepting such applications, but said the rules are broken more often than they are followed. (Click here for more
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.